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Current therapeutic options offer the
possibility of enabling the patient to lead
as normal a life as possible with minimal
interference from the condition. Successful
outcomes for asthma control necessitate
health care professionals to understand the
experiences, expectations and needs of male
and female asthma patients of all ages.
Introduction
International asthma management
guidelines state that the aim of therapy is
to achieve control of asthma (Table1).1
Inadequate control of asthma contributes to
increased morbidity and mortality and
places considerable restrictions on the
physical, emotional and social aspects of
persons with asthma. These restrictions
have a substantial negative impact on the
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Asthma is a common chronic condition which usually presents
with the symptoms of wheeze, cough, shortness of breath and
chest tightness due to the underlying inflammation and
bronchoconstriction present in the lungs. This condition
causes considerable distress to the patient and negatively
affects other members of the family. To date we cannot cure
asthma, but we can aim to achieve optimum control as
recommended by international guidelines.
emotional impact of asthma is felt across all
age groups, however it is particularly
evident in children, who experience feelings
of anger, frustration, sadness and guilt
because of their condition.4 Persons with
asthma often choose to refrain from
engaging in social activities or do so with
reluctance and possibly trepidation due to
fear of experiencing an exacerbation.5
Inadequate control, leads to increased
asthma symptoms, decreased quality of life
and could promote a lack of confidence in
the medical care being given. The lack of
perceived benefit from therapy decreases
adherence to prescribed medication and in
some cases also stimulates patients to
substitute medication with alternative
therapies, which are not validated by
conventional standards, potentially leading
to detrimental effects on health.  It is
therefore essential to provide patients with
therapy which is safe, effective at the
physiological level, provides adequate
symptom control and allows them to live a
normal life i.e. patients need to be provided
with medication that works and that they
perceive is working.
The use of guidelines in the
management of asthma
While guidelines are well accepted as
being an effective tool in the management
of asthma, studies show that the desired
degree of control is still not being
achieved.6 Various reasons have been cited
for this, the main ones being inappropriate
implementation of guidelines, under
treatment of asthma and inefficient
communication between health care
provider and patient.7  Evidence shows that
appropriate management according to
guidelines, close monitoring and increased
access to health care professionals i.e.
delivery of pharmaceutical care, improves
therapeutic outcomes and patient
Table 1: GINA defined asthma control1
• Minimal (ideally no) cough, wheeze, chest tightness, breathlessness
including nocturnal symptoms
• Minimal (infrequent) exacerbations
• No emergency room visits
• Minimal (ideally no) use of prn short acting ß
2
 agonist
• No limitations on activities, including exercise
• Peak expiratory flow (PEF) circadian variation of less than 20%
• (Near) normal PEF
• Minimal or no adverse effects from medication
Effect of asthma on
quality of life
The limitations placed on physical
activities, such as getting around the
house, shopping, gardening, exercising and
engaging in sports are significantly more of
a burden on asthma suffers than on
patients with other chronic conditions, such
as diabetes, and are even more pronounced
in young women with asthma. 2,3  The
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satisfaction.8 The close monitoring of the
patients permits adaptation of treatment to
the current severity of the disease,
addressing the variable and dynamic nature
of this chronic condition.
Achieving and maintaining control of
asthma in daily clinical practice, in the real
world as opposed to clinical trials, is
challenging. It is therefore essential for
health care professional to be  equipped
with the necessary skills which include
appropriate diagnostic tools and the ability
to select the appropriate therapy according
to the patient’s needs. The selection of the
correct medication/s-dose, dosing frequency
and a delivery system which is appropriate
and acceptable to the patient is of primary
importance. The ability to listen to and
address the patients’ concerns is paramount
if successful outcomes are desired. It is
important for the health care professional
to enquire what the expectations of the
patient are and to try and fulfil them
adequately. A study conducted with school
children demonstrated the feeling of anger
experienced by adolescents with asthma
who felt ignored by their doctors as the
latter choose to address their parents when
determining the degree of asthma control.4
Such evidence indicates vast room for
improvement and the need for health care
professionals to have better training in
communication skills.
The stepwise approach to management
in asthma (Table 2) is ideal as it is flexible
and therapy is initiated at the relevant step
of asthma severity and stepped up when
control is not achieved. A clear indication
of inadequate control is the use of reliever
medication more than 4 times a day. The
patient is stepped up only after inhaler
technique and degree of adherence to
therapy have been assessed.
Pharmacotherapy
Control of asthma is achieved by using
controller medications daily on a long term
basis. Inhaled glucocorticoids are, to date,
the most effective controller,
anti-inflammatory medications available.
Inhaled glucocorticoids are indicated for all
levels of asthma severity except when
asthma is intermittent. A patient’s asthma
is classified as intermittent only if
(i) symptoms are experienced less than
once a week over a period of 3 months and
are brief, (ii) nocturnal symptoms are
experienced no more than twice a month
and (iii) lung function between episodes is
normal. If, however, rapid acting
ß2 agonists are needed more than once a
week over a 3 month period, therapy should
be stepped up and inhaled glucocorticiods
introduced. 1
A dose of 500µg of beclomethasone
dipropionate daily (or equivalent - Table 3)
controls most adult asthma. In general, at
this dose or less, systemic side-effects are
not a problem in adults, although this may
vary on a patient to patient basis. Should a
dose of 500µg of beclomethasone
dipropionate, prove to be insufficient to
control asthma it is preferable to add on
another class of controller medication, such
as a long-acting (LA) ß2 agonist, rather
than increase the dose of inhaled
glucocorticoids.9  Other alternative add-on
controller medications include anti-
leukotrienes and sustained release
theophylline. Control should be maintained
at the lowest dose of inhaled glucocorticoid
possible. It is recommended that the
patient is reviewed on a regular basis,
ideally every 3 months. If a patient is well
controlled and stable, a gradual reduction in
dose by 25-50% is suggested. When
stepping down, the factors to be taken into
account include severity of asthma, side-
effects/beneficial effects of treatment and
patient preference. 1,10,11 It should however
be emphasised that the selection of the
appropriate dose of inhaled glucocorticoid
and additional controller medication for a
patient requires clinical judgement. Some
patients may benefit from high doses of
inhaled glucocorticoids, as this would
permit control without the use of oral
glucocorticoids, whose side-effect profile is
by far more pronounced.12,13
There is a significant body of evidence
which suggests that the combination of a
long acting ß2 agonist such as salmeterol/
formoterol and an inhaled glucocorticoid is
the most effective means of controlling
asthma in the majority of patients. There is
a strong scientific rational for the
combination of these two types of
controller medication since they each target
different and complimentary aspects of the
inflammatory process. 14 ß2 agonists and
glucocorticoids interact in a beneficial way.
Glucocorticoids prevent the development of
tolerance to ß2 agonists, while the latter
probably potentiate the local anti-
inflammatory action of glucocoticoids.15
This evidence has led to the development of
fixed combination inhalers of fluticasone/
salmeterol (Seretide®) and budesonide/
formoterol (Symbicort®) in one inhaler
device.16,17  Various clinical trials have
Drug Low Dose Medium Dose High Dose
Beclomethasone dipropionate 200-500µg 500-1000µg >1000µg
Budesonide 200-400µg 400-800µg >800µg
Fluticasone 100-250µg 250-500µg >500µg
Table 3: Estimated equipotent doses of inhaled glucocorticoids in adults1
Severity Daily Controller Medication
Step 1: Intermittent Asthma None
Step 2: Mild Persistent Inhaled Beclomethasone dipropionate
<500µg
Step 3: Moderate Persistent Inhaled Beclomethasone dipropionate
200-1000µg + LA ß2 agonist
Step 4: Severe Persistent Inhaled Beclomethasone dipropionate
>1000µg + LA ß2 agonist + oral
prednisolone
Table 2: Medication by severity (Adults)1
  Short acting ß
2
  agonist prn not more than 3-4 times daily
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demonstrated the effectiveness of
combination therapy in controlling
asthma.18,19,20 Since combination therapy
achieves better control of asthma than
doubling the dose of inhaled
glucocorticoids it has a very important
steroid-sparing role, thus enabling
attainment and maintenance of control at
the lowest possible dose of inhaled
glucocorticoid.21,22 Recently published
evidence has shown that combination
therapy can achieve guideline defined
asthma control (Table1).23 Combination
therapy is now regarded as the new ‘gold
standard’ of asthma therapy.24
In practice combination therapy offers
the advantage of controlling asthma using
two complementary controller medications
delivered through one inhaler device, with a
convenient twice daily dosage increasing
the possibility of adherence to therapy. It is
delivered as a dry power inhaler offering the
advantage of increased ease of use.
Adherence to therapy
Adherence to therapy plays a major role
in asthma control. Adherence is influenced
by dosage regimen, beliefs regarding
effectiveness, recall of dosing times and
access to therapy.25 Data pertaining to the
local situation indicates that, while access
to medication is not a problem, 55% of
patients studied were unable to mention
their asthma drugs and/or did not follow
their regimen, while 97% had barriers to
adherence due to recall, indicating ‘sporadic
non-adherence’ which can be addressed by
adjusting and simplifying the regimen.
Interestingly, 60% of patients had negative
beliefs regarding the effectiveness of their
medication, stating that they did not
believe their asthma medicine worked well
and/or that their prescribed therapy
bothered them.26 It is therefore imperative
for prescribers to identify and take into
account potential barriers to adherence in
order to achieve better outcomes.
Conclusion
Attaining and maintaining control in
asthma is complex. It entails more than
appropriate drug selection. Unless the
healthcare provider is willing to understand
the patient’s perspective of asthma control,
listen to the patient’s concerns and address
any issues causing anxiety to the patient,
control is bound to be lost. In this day and
age we are also sufficiently aware that there
is a relationship between gender and health
and it is necessary to take into
consideration sex and gender differences
when treating a male or a female patient
with asthma.27 Health care professionals
need to work with the patient and adopt a
holistic approach to improve all
aspects of asthma control thus enhancing
the quality of life of the individual.
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